Iovance Q1 Earnings Review: Not Enough Data To Draw Conclusions On Amtagvi [Seeking Alpha]
Iovance Biotherapeutics, Inc. (IOVA)
Last iovance biotherapeutics, inc. earnings: 2/25 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
iovance.com
Company Research
Source: Seeking Alpha
Iovance secured a historic approval for a first solid tumor targeting cell therapy in mid-Feb, triggering overnight gains of close to 100%. Now, the market is turning its attention to revenue figures and patient enrollment for Amtagvi, approved to treat melanoma. Yesterday's updates provided by management seemed upbeat, but analysts had many questions and the share price has been falling today. In this post, I provide a thorough overview of the state of play post Q1 '24 earnings, and speculate on key themes that will dictate IOVA stock price movements going forward. Iovance Biotherapeutics Overview Iovance Biotherapeutics, Inc. NASDAQ: IOVA ), the San Carlos, California-based biotech that secured a historic first approval for a solid tumor targeting cell therapy earlier this year, announced its Q1 2024 earnings yesterday. Iovance's tumor infiltrating lymphocyte ("TIL") cell therapy candidate, lifileucel, achieved a 31.4% overall response rate in a study of 73 patients wit
Show less
Read more
Impact Snapshot
Event Time:
IOVA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IOVA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IOVA alerts
High impacting Iovance Biotherapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
IOVA
News
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) [Yahoo! Finance]Yahoo! Finance
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)GlobeNewswire
- The sun's out, so you need to think about prevention of this type of cancer [CNN]CNN
- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.MarketBeat
- Why Iovance Stock Is Down 18% Today [Yahoo! Finance]Yahoo! Finance
IOVA
Earnings
- 5/9/24 - Beat
IOVA
Sec Filings
- 5/17/24 - Form DEFA14A
- 5/10/24 - Form S-8
- 5/9/24 - Form 10-Q
- IOVA's page on the SEC website